# Vibrant Therapeutics

> Vibrant Therapeutics (VibrantX) is a clinical-stage biotechnology company building intelligent, logic-gated antibody therapeutics that switch on only inside diseased tissue. By pairing computational protein design with high-throughput wet-lab validation across its BumbleBee, LogicBee and NeuroBee platforms, Vibrant develops conditionally activated, multi-specific antibody prodrugs for oncology, autoimmune, inflammatory and neurological diseases. Its lead program, VIB305, is a logic-gated masked T-cell engager for EGFR-positive solid tumors that has received FDA IND acceptance.

- **Founded:** 2019
- **Headquarters:** Cambridge, Massachusetts, United States (with operations in Guangzhou, China)
- **Founders:** Larry Wang (Co-Founder, Co-CEO & CTO)
- **Team size:** Approximately 10-50 employees (Cambridge, MA and Guangzhou, China)
- **Products:** BumbleBee platform, LogicBee platform, NeuroBee platform, VIB305
- **Notable:** Raised $61M in 2026, bringing total capital raised to roughly $100M, with Pfizer Ventures and Apricot Capital as new investors., Received US FDA IND acceptance for lead program VIB305, a logic-gated masked T-cell engager for EGFR-positive solid tumors., Built three integrated drug-design platforms - BumbleBee, LogicBee and NeuroBee - spanning antibody engineering, proteomics-driven targeting and blood-brain-barrier delivery.

## Products & services

- **BumbleBee platform** — Combines advanced computing with multi-specific antibody engineering to streamline discovery and design safer, more effective biotherapeutics.
- **LogicBee platform** — Uses proteomics analysis to identify proteins that differ between healthy and diseased tissue, enabling logic-gated prodrugs that activate only in the disease microenvironment.
- **NeuroBee platform** — Engineered to deliver antibody therapeutics across the blood-brain barrier for central nervous system diseases.
- **VIB305** — Lead program: a logic-gated, dual-targeting masked T-cell engager (mTCE) for EGFR-positive solid tumors; FDA IND accepted, with early-phase activity in Australia and China.

## Achievements

- Raised $61M in 2026, bringing total capital raised to roughly $100M, with Pfizer Ventures and Apricot Capital as new investors.
- Received US FDA IND acceptance for lead program VIB305, a logic-gated masked T-cell engager for EGFR-positive solid tumors.
- Built three integrated drug-design platforms - BumbleBee, LogicBee and NeuroBee - spanning antibody engineering, proteomics-driven targeting and blood-brain-barrier delivery.
- Advanced early-phase clinical activity across Australia and China while expanding US operations from Cambridge.

## Latest updates

- **2026-01** — Raised $61M in new financing (Pfizer Ventures, Apricot Capital and others) and appointed Han Lee, Ph.D. as co-CEO; total capital raised reaches ~$100M.
- **2026-01** — Lead program VIB305 received US FDA IND acceptance for EGFR-positive solid tumors.

## Links

- Website: https://www.vibrantx.com
- LinkedIn: http://www.linkedin.com/company/vibrantx

---

Profile page: https://yespress.io/vibrant-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-10